J Gynecol Oncol.  2008 Dec;19(4):279-279. 10.3802/jgo.2008.19.4.279.

Clinical significance of postoperative CA-125 level after primary cytoreductive surgery in ovarian cancer

• Kim HS
• Park NH

• KMID: 2173421
• DOI: http://doi.org/10.3802/jgo.2008.19.4.279

Abstract

No abstract available.

MeSH Terms

Ovarian Neoplasms

Reference

1. Juretzka MM, Barakat RR, Chi DS, Iasonos A, Dupont J, AbuRustum NR, et al. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy. Gynecol Oncol. 2007. 104:176–180.

2. Crawford SM, Peace J. Does the nadir CA125 concentration predict a longterm outcome after chemotherapy for carcinoma of the ovary? Ann Oncol. 2005. 16:47–50.

3. Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Serum CA125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer. Onkologie. 2008. 31:315–320.

4. Eltabbakh GH, Mount SL, Beatty B, Simmons-Arnold L, Cooper K. Clinical and molecular differences between clear cell and papillary serous ovarian carcinoma. J Surg Oncol. 2006. 93:379–386.

5. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study. J Clin Oncol. 2000. 18:106–115.

6. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatincyclophosphamide in women with advanced epithelial ovarian cancer: Threeyear results. J Natl Cancer Inst. 2000. 92:699–708.